LEAP Technologies and Bruker collaborate on novel HDX solution for protein conformation studies

LEAP Technologies and Bruker collaborate on novel HDX solution for protein conformation studies

June 06, 2016

From Bruker:

Bruker Introduces Novel HDX Solution for Protein Conformation Studies

San Antonio, Texas, June 6, 2016 – At ASMS 2016, Bruker today announced a new Hydrogen Deuterium Exchange (HDX) workflow on Bruker’s new HDX Solution™.  The Bruker HDX Solution enables an automated and reliable HDX-MS workflow combining the LEAP H/D-X PAL™(LEAP Technologies, part of the Trajan family) with Bruker’s market-leading ultra-high mass resolution maXis II ETD UHR-QTOF system, and the Sierra Analytics HDExaminer software. The Bruker HDX Solution delivers correct monoisotopic accurate-mass assignments for quantitative results from H/D ratios, which enables ready access to biomolecular structural insights with greater certainty and confidence.

Read the full announcement at the Bruker website.


Photo from Bruker: Key components of the robotic setup for automatic HX-MS experiments

 




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More